Portfolio company
Architect Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This discovery-stage company develops oral small-molecule drugs for immunology and oncology patients by utilizing carbon-hydrogen bond activation to design novel chemical architectures.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Forward Therapeutics
The company develops oral small-molecule medicines for patients with chronic immunological and inflammatory disorders.
Promakhos
This company develops oral small-molecule immunotherapies that restore immune system function to treat patients with chronic inflammatory diseases.
PsiThera
PsiThera develops oral small-molecule medicines for patients with immune and inflammatory diseases, using a physics-driven platform to target proteins traditionally requiring injections.
Auron Therapeutics
This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.
Matchpoint Therapeutics
This biotechnology company develops oral covalent small molecule medicines to treat patients with autoimmune and inflammatory diseases.
Sitryx Therapeutics
The company develops oral small molecule therapies to treat patients with autoimmune and inflammatory diseases by regulating immune cell metabolism.
Principia Biopharma
The company develops oral small molecule therapies for patients with immune-mediated diseases and cancer.
Atavistik Bio
This biotechnology company develops oral allosteric small molecule therapeutics for patients with rare hematological diseases and cancers.